Literature DB >> 24459094

Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

Dennis L Buckley1, Craig M Crews.   

Abstract

Traditionally, biological probes and drugs have targeted the activities of proteins (such as enzymes and receptors) that can be readily controlled by small molecules. The remaining majority of the proteome has been deemed "undruggable". By using small-molecule modulators of the ubiquitin proteasome, protein levels, rather than protein activity, can be targeted instead, thus increasing the number of druggable targets. Whereas targeting of the proteasome itself can lead to a global increase in protein levels, the targeting of other components of the UPS (e.g., the E3 ubiquitin ligases) can lead to an increase in protein levels in a more targeted fashion. Alternatively, multiple strategies for inducing protein degradation with small-molecule probes are emerging. With the ability to induce and inhibit the degradation of targeted proteins, small-molecule modulators of the UPS have the potential to significantly expand the druggable portion of the proteome beyond traditional targets, such as enzymes and receptors.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug design; inhibitors; proteasome; protein degradation; ubiquitin

Mesh:

Substances:

Year:  2014        PMID: 24459094      PMCID: PMC4348030          DOI: 10.1002/anie.201307761

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   16.823


  167 in total

1.  Will the ubiquitin system furnish as many drug targets as protein kinases?

Authors:  Philip Cohen; Marianna Tcherpakov
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

Review 2.  Catalytic mechanism and assembly of the proteasome.

Authors:  António J Marques; R Palanimurugan; Ana C Matias; Paula C Ramos; R Jürgen Dohmen
Journal:  Chem Rev       Date:  2009-04       Impact factor: 60.622

3.  Stuck in the middle: drugging the ubiquitin system at the e2 step.

Authors:  J Wade Harper; Randall W King
Journal:  Cell       Date:  2011-06-24       Impact factor: 41.582

4.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors.

Authors:  M Bogyo; J S McMaster; M Gaczynska; D Tortorella; A L Goldberg; H Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.

Authors:  Michael Groll; Celia R Berkers; Hidde L Ploegh; Huib Ovaa
Journal:  Structure       Date:  2006-03       Impact factor: 5.006

6.  Rational design and binding mode duality of MDM2-p53 inhibitors.

Authors:  Felix Gonzalez-Lopez de Turiso; Daqing Sun; Yosup Rew; Michael D Bartberger; Hilary P Beck; Jude Canon; Ada Chen; David Chow; Tiffany L Correll; Xin Huang; Lisa D Julian; Frank Kayser; Mei-Chu Lo; Alexander M Long; Dustin McMinn; Jonathan D Oliner; Tao Osgood; Jay P Powers; Anne Y Saiki; Steve Schneider; Paul Shaffer; Shou-Hua Xiao; Peter Yakowec; Xuelei Yan; Qiuping Ye; Dongyin Yu; Xiaoning Zhao; Jing Zhou; Julio C Medina; Steven H Olson
Journal:  J Med Chem       Date:  2013-05-06       Impact factor: 7.446

7.  An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation.

Authors:  Yeong Sang Kim; Katelyn Nagy; Samantha Keyser; John S Schneekloth
Journal:  Chem Biol       Date:  2013-04-18

8.  Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.

Authors:  Bryan M Wittmann; Andrea Sherk; Donald P McDonnell
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

Authors:  Yuan Yuan; Yu-Min Liao; Chung-Tsen Hsueh; Hamid R Mirshahidi
Journal:  J Hematol Oncol       Date:  2011-04-20       Impact factor: 17.388

Review 10.  Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets.

Authors:  Lynn Bedford; James Lowe; Lawrence R Dick; R John Mayer; James E Brownell
Journal:  Nat Rev Drug Discov       Date:  2010-12-10       Impact factor: 84.694

View more
  46 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

Review 2.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

3.  Protein degradation: Prime time for PROTACs.

Authors:  Raymond J Deshaies
Journal:  Nat Chem Biol       Date:  2015-09       Impact factor: 15.040

4.  Covalent Tethering of Fragments For Covalent Probe Discovery.

Authors:  Stefan G Kathman; Alexander V Statsyuk
Journal:  Medchemcomm       Date:  2016-01-28       Impact factor: 3.597

5.  A Novel Destabilizing Domain Based on a Small-Molecule Dependent Fluorophore.

Authors:  Raul Navarro; Ling-Chun Chen; Rishi Rakhit; Thomas J Wandless
Journal:  ACS Chem Biol       Date:  2016-06-06       Impact factor: 5.100

Review 6.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

7.  Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.

Authors:  Mark A Nakasone; Timothy A Lewis; Olivier Walker; Anita Thakur; Wissam Mansour; Carlos A Castañeda; Jennifer L Goeckeler-Fried; Frank Parlati; Tsui-Fen Chou; Ortal Hayat; Daoning Zhang; Christina M Camara; Steven M Bonn; Urszula K Nowicka; Susan Krueger; Michael H Glickman; Jeffrey L Brodsky; Raymond J Deshaies; David Fushman
Journal:  Structure       Date:  2017-11-16       Impact factor: 5.006

8.  Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome.

Authors:  Yuntao Shi; Marcus J C Long; Masha M Rosenberg; Shican Li; Aimee Kobjack; Philip Lessans; Rory T Coffey; Lizbeth Hedstrom
Journal:  ACS Chem Biol       Date:  2016-10-18       Impact factor: 5.100

Review 9.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

Review 10.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.